Biocartis announces breast cancer research collaboration with US Mayo Clinic

Esme Needham | January 14, 2026 | News story | Research and Development |  Biocartis, Mayo Clinic, Oncology, breast cancer 

Biocartis has announced a research collaboration with Mayo Clinic in the US, aiming to develop an accelerated sample-to-answer test resulting in quicker and more effective treatment for breast cancer patients.

As part of the collaboration, Mayo Clinic will share its extensive clinical knowledge, as well as samples and pathology services. The test is currently in the investigational stage, but Biocartis and Mayo Clinic hope to develop, validate and market it at pace.

Biocartis is a molecular diagnostics company whose proprietary Idylla platform is able to deliver molecular biomarker results in three hours. Its diagnostic test portfolio includes tests for areas such as lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer.

Mayo Clinic is a nonprofit organisation specialising in education, research and clinical practice. Matthew P Goetz, medical oncologist at Mayo Clinic, said: “Optimal care depends on timely access to test results. Rapid local diagnostics can shorten the time to determine patients’ appropriate therapeutic pathway. Our goal is to help make faster testing available to breast cancer patients.”

“Our goal is to use this as a first step toward expanding into larger markets, including gene signatures, patient monitoring and early detection,” said Roger Moody, CEO of Biocartis. “Biocartis has an accomplished history of successful collaborations with academic and pharmaceutical industry partners that have led to the first sample to answer companion diagnostic approved by the US FDA as well as CE-in vitro diagnostic registrations.”